

The COSEVAST Study: Unravelling the role of Arterial Stiffness in COVID-19 Disease severity

Dr.Sanjeev Kumar *, MS,MCh,Dr.Neeraj Kumar , M.D., Dr.Abhyuday Kumar, MD, Dr.Divendu Bhushan, MD, Dr.Amarjeet Kumar, MD, Dr.Ajeet Kumar, MD, Dr.Veena Singh, MS,MCh, Dr.Prabhat Kumar Singh, MD.

All India Institute of Medical Sciences, Patna, INDIA

Abstract Background: Based on the detailed review of available research and case studies reported in reputed international journals, it can be concluded that endothelial damage (Endotheliitis) both in small and large arteries may be an important factor of morbidity and mortality in COVID-19 patients. Arterial stiffness due to Endothelial Dysfunction has been established as an independent and specific marker of various chronic cardiovascular diseases.

Objective: Our objective was to examine functional impairment of the arteries in COVID-19 disease and establish the non-invasive measurement of Arterial Stiffness as an independent marker of disease severity.

Methods: We recorded the Arterial Stiffness of 23 Mild, 21 Moderate and 20 Severe COVID-19 patients grouped on latest NIH severity criteria. We observed Arterial Stiffness of COVID-19 patients with standard parameters like non-invasive Carotid-Femoral Pulse Wave Velocity (cfPWV), Age-Normalized increase in cfPWV (ANI_cfPWV).

Results: Moderate and Severe COVID-19 patients have extremely elevated arterial stiffness than Mild patients. In Mild patients, cfPWV (829.1 ± 139.2 cm/s) was extremely significantly lower than both Moderate (1067 ± 152.5 cm/s, $P < 0.0001$) and Severe (1416 ± 253.9 cm/s, $P < 0.0001$) patients. ANI_cfPWV in Moderate and Severe patients was significantly higher than Mild patients. (Mild: 101.2 ± 126.1 cm/s; Moderate: 279 ± 114.4 cm/s; Severe: 580.1 ± 216.4 cm/s; intergroup $P < 0.0001$).

Conclusion: Our findings strongly suggest that arterial stiffness can be an independent and accurate marker for objective risk stratification and therapeutic alleviation of the acute cardiovascular complications like MODS in COVID-19.

Keywords : COVID-19, Endotheliitis, Arterial Stiffness, Pulse Wave Velocity, Severity, Cardiovascular Complications, Multiple Organ Dysfunction Syndrome (MODS)

Correspondence:

* First Author Corresponding Author : Dr. Neeraj Kumar, M.D.; Affiliation: Assistant Professor; Full Address: Room no.503, 5th Floor, OT Complex IPD, B-Block, Clinical coordinator-COVID-19, All India Institute of Medical Sciences (AIIMS), Patna, Bihar, India PIN 801505 drneerajk@aiimspatna.org ; Neeraj.jlnmc@gmail.com

Background

The acute respiratory viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is named as Corona Virus Disease 2019 (COVID-19) and is declared as a pandemic by the World Health Organization (WHO). As of first week of December 2020, there are around 9.5 million confirmed cases of COVID-19 in India alone, including more than 130,000 deaths. There is a rise in the number of cases every day, affecting millions of people around the globe and resulting in a public health emergency. Moreover, medical professionals are finding it very difficult to manage the disease in terms of treatment options. Many drugs have been tried under emergency use authorization like Remdesivir or convalescent plasma without much success. Preventive measures like vaccines are being discovered and some are in advanced stages of testing. [1] There is an urgent need to stratify the risk, guide the therapy in a proper manner and control the short and long term complications like target organ damage. Although this disease primarily looks like an acute pulmonary disease, the manifestation of cardiovascular damage strongly suggests that there is an arterial involvement. Various studies have pointed to severe and acute endothelial damage in moderate to severe cases of COVID-19. There is a need to clearly establish relationship between the arterial damage and severity in such patients to improve understanding of the pathophysiology of the disease. Such evidence may radically change the therapeutic strategy or give rise to a new therapy to improve the prognosis and lessen the burden on the healthcare facilities to a large extent.

Introduction

It has been extensively highlighted that SARS-CoV-2 affects the RAS (Renin-Angiotensin System) and the Angiotensin converting enzyme-2 receptors play most important role in presentation of the COVID-19 disease. [2-5] SARS-CoV-2 infects the host using the Angiotensin Converting Enzyme 2 (ACE2) receptor, which is expressed in several organs, including the lung, heart, kidney, brain and intestine. This is due to the fact that ACE2 is a type I membrane protein expressed on endothelial cells in the kidney, heart, gastrointestinal tract, blood vessels, and, importantly, lung AT2 alveolar epithelial cells, which are particularly prone to viral infection. In COVID-19, Sepsis is observed as the most important cause of target organ damage leading to morbidity and subsequent mortality. As SARS-CoV-2 is a new coronavirus, and its cardiovascular complications and the underlying pathology is still emerg-

ing. However, it is accepted that the virus affects the total vasculature in human body and this infection becomes a highly accelerated process for the target organ damage. In the case of acute cardiological manifestation, it is termed as Acute COVID-19 Cardiovascular Syndrome (ACovCS) by the American Heart Association's white paper. [6]

European Society of Cardiology (ESC) has published a detailed review paper [7] on the involvement of various cardiovascular target organs in COVID-19 disease. This review clearly establishes a close two-way relationship between COVID-19 disease and all cardiovascular diseases (CVD). Even though clinical symptoms of the disease with initial infection show respiratory distress and severe pneumonia, in the later stages the complete cardiovascular system gets affected with direct and indirect damage to other organs dependant on it. The prognosis is even worse in the patients with pre-existing cardiovascular system involvement. Cardiovascular involvement in COVID-19 is seen as key manifestations. In particular, the endothelial cells or pericytes inflammation could lead to severe microvascular and macrovascular dysfunction. Every stage of COVID-19 disease which leads to heart or similar target organ failure shows arterial involvement, basically starting from endothelial cell involvement. In COVID-19, Sepsis is observed as the most important cause of target organ morbidity and subsequent mortality. In Sepsis, the severity is directly associated with Endothelial dysfunction. It may be deduced that pathophysiology of Sepsis is mainly dependent on level of integrity and functioning endothelium. Hence an objective assessment of Endothelial function may serve as a more accurate prediction tool and a target for therapies aimed at ameliorating Sepsis occurring in later stages of COVID-19.

The best way to assess Endothelial Dysfunction is assessment of its clinical manifestation, i.e. increase in the Arterial Stiffness. There have been multiple in vitro and in vivo studies which have shown that the vascular endothelium is an important factor in setting the vascular tone and endothelial dysfunction leads to arterial stiffness. [8] Arterial stiffness and enhanced wave reflections are markers of cardiovascular disease and independent predictors of cardiovascular risk. [9-12] Stiffening of the large arteries and enhanced wave reflections lead to increased left ventricular (LV) afterload, disturbed coronary perfusion, and mechanical fatigue of the arterial wall. [13]

The relationship between systemic inflammation and arterial stiffness is well established in the literature. [14] The cause-and-effect relationship that acute systemic inflammation leads to deterioration of large-artery stiffness. Given the importance of aortic stiffness for cardiovascular function and risk, the therapeutic interventions with anti-inflammatory properties will be potentially very useful in reducing the COVID-19 morbidity and mortality.

Findings in a study [15] on induced inflammation have shown that an acute inflammation caused a temporary increase in central blood pressure and arterial stiffness in terms of Pulse Wave Velocity. This implies the increased risk of cardiovascular events associated with acute systemic inflammation.

tion in the COVID-19.

COVID-19 disease related worldwide research and proposed mechanisms pointed to patho-physiological involvement of endothelial dysfunction and arterial wall compromise. However, there was no empirical evidence of the functional compromise of arterial walls.

Hence, a study was urgently needed to study increase in Arterial Stiffness in COVID-19 patients due to systemic inflammation so as to stratify the risk and mitigate further cardiovascular damage with guided therapeutic treatment based on severity of arterial stiffness.

This pressing need is justified by a comprehensive review article [16] published after the present study was envisaged. We hope that the findings from our study will fulfill the need to a large extent.

Materials and Methods

The present prospective non-randomized observational study titled - "To study the relationship of COVID-19 SEverity with Arterial Stiffness : A prospective cross sectional study" ('COSEVAST study') was conducted in the COVID-19 ICU, Medical ICU and various wards of dedicated Covid hospital at AIIMS, Patna, Bihar, India. The study protocol, informed consents and other trial-related documents received the written approval of Institutional Ethics Committee (IEC No. AIIMS/Pat/IEC/2020/595) AIIMS Patna, Bihar, India. The study design was registered with the Clinical Trials Registry of India (CTRI No. CTRI/2020/10/028489).

All COVID-19 patients were subject to RT-PCR test and had a confirmed infection of SARS-Cov-2 virus. Participants, after understanding the study protocol and procedures, gave their written informed consent for the study. The exclusion criteria were known history of any of these diseases - Diabetes Mellitus (DM), Hypertension (HTN), CAD, Stroke, Neuropathy, PAD, Nephropathy, MI, Pregnancy, Peripheral Oedema or inflammation, Cardiac arrhythmia and any pre-existing Cardiovascular disorder.

Patient Categorization. The selected patients after fulfilling the inclusion criteria were grouped into three categories - Mild, Moderate and Severe category based on latest NIH Guidelines [17] as-

A. Mild category: Individuals with mild signs and symptoms like fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell but who do not have shortness of breath, dyspnea, or abnormal chest imaging.

B. Moderate category: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen (SpO₂) 94% on room air at sea level and

C. Severe category: Individuals who have saturation of oxygen (SpO₂) <94% on room air at sea level, a respiratory rate of >30 breaths/min, PaO₂/FiO₂ <300 mmHg, or lung infiltrates >50%.

The range of treatment protocols followed in this study

were based on our institutional standard operating procedure (SOP) for the management of COVID-19 patients based on their clinical severity category and it included antivirals (Remdesivir), broad spectrum antibiotics, low molecular weight heparin (Enoxaparin) immunomodulators (steroids, Tocilizumab) and supportive management (oxygen via nasal cannula, face mask, non-rebreathing face mask; non-invasive or invasive mechanical ventilation; awake proning).

Measures of Arterial Stiffness. With the increased awareness about Arterial Stiffness during pre-Covid era, clinicians have started adding measurement and treatment of underlying arterial stiffness in their clinical practice.[18] International healthcare societies like the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) have included PWV measurement in their 2003 guidelines for management of hypertension.[19,20]

Arterial stiffness assessed by PWV (pulse wave velocity) correlates to the number of treated and non-treated cardiovascular risk factors, atherosclerotic events and cardiovascular risk as predicted by the Framingham risk equations.[21] PWV is also positively correlated with carotid intima media thickness, a marker of atherosclerotic burden in the coronary arteries.[22] In this study, Arterial stiffness is primarily measured in terms of pulse wave velocity, which is a recognized gold standard.

Pulse wave velocity, which is a relevant indicator of arterial stiffness, can be measured non-invasively with a variety of devices. However, since COVID-19 is a highly contagious disease, a fully automatic device with minimal contact, lesser exposure time and proximity with the patient need to be maintained.[23] It would be always challenging for observer to conduct the entire test by wearing full Personal Protection Equipment (PPE) kit. So a test device which avoids close proximity, longer exposure and holding a probe while testing, was needed for the study. We found that the medical device PeriScope™ (Manufactured by M/s. Genesis Medical Systems Pvt. Ltd., Hyderabad, India) was suitable as it fulfilled all the above requirements. PeriScope is a clinically validated and tested the non-invasive medical device used to measure Brachial Ankle PWV (baPWV) and derives the Carotid Femoral PWV (cfPWV), which is equivalent to aortic PWV.[24] A population-based study with 3969 subjects using 'PeriScope' has established the role of arterial stiffness in various cardiovascular diseases (CVD).[25] Aortic pressure values also have been established as surrogate markers for arterial stiffness. PeriScope estimates the Aortic Pressures and the Systolic Pressure Augmentation (AugP) at the root of the Aorta due to the increased arterial stiffness. The Pressure Augmentation Index (AIx) values found by PeriScope were compared with other internationally accepted non-invasive device and found to be very accurate and highly comparable.[26] All the tests were conducted as per the standard procedure given in the operator's manual of PeriScope. Electrocardiogram (ECG) Electrodes were placed on ventral surface of both wrists and medial side of ankles, and BP cuffs were wrapped on both upper arm brachial artery and tibial artery above ankles. All the ECG and pressure recordings

were done automatically and data were stored in the personal computer for analysis. The built in validated proprietary algorithm within the PeriScope PC software calculated the following parameters from the waveforms, which were stored in the computer for analysis like - systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), heart rate (HR), carotid-femoral pulse wave velocity (cfPWV).

Data Analysis. Data are expressed as mean \pm SD. Statistical analysis was performed using the GraphPad PRISM software version 5.03 (GraphPad software Inc., San Diego, California, USA). Difference between all the groups were evaluated by unpaired Student's 't' test and ANOVA. Linear regression analysis and Pearson's correlation analysis were performed to evaluate the association between various confounding factors to rule out interdependence. Probability values of $P < 0.05$ were considered to indicate statistical significance. All P values are two-tailed.

Results

Total 64 patients (42M/22F) patients were recruited in the study. The patient demographic variables were shown in Table 1. All the patients were under the healthy and normal BMI category. Since the patients did not have any known comorbidity, Lipid profile or Blood sugar levels were not taken into consideration. The minimum age was 18 years and maximum was 69 years. Although there was a difference between the mean values of Age, Weight and height; but it was statistically not significant between the groups. Figure 2 shows the graphical representation of overall patient demographics as age, weight, height and BMI as (Figure 2a, b, c and d).

Although Arterial Blood Gas (ABG) Analysis was carried out for all the patients, it was not possible to find the point-of-time PaO₂% value of each patient at the time of arterial stiffness test. For this reason, stat SpO₂% reading was taken as the measure of Oxygen saturation for accurate comparison. Also, since it was not ethically correct[27] and clinically possible to check oxygen saturation without or by removing external Oxygen support in all cases, the best way to quantify these severity was taking ratio of SpO₂% and FiO₂% as an indication of respiratory distress. Earlier studies and guidelines suggest SpO₂% to FiO₂% (SF) ratio is a reliable noninvasive surrogate for PaO₂% to FiO₂% (PF) ratio [28-30] especially in COVID-19 patients. All of the Severe patients were admitted into the COVID-19 ICU whereas all of the Mild patients were admitted into COVID-19 and General wards. Some of the Moderate patients were in the ICU and some were in the General ward with Oxygen support. The statistical analysis of the segregation criteria is as shown in Table 2. The Patient categorization can be clearly visualized by graphical representation (Figure 3) of the data. The Figure 3a shows statistical analysis of respiration rate of the three groups, Figure 3b shows FiO₂%, Figure 3c shows SpO₂% whereas Figure 3d shows the statistical analysis of SF ratio (SpO₂/FiO₂) respectively.

CARDIO VASCULAR RISK ANALYSIS

INTERPRETATION SUMMARY*	TEST REPORT AND OBSERVATIONS				
Est. Functional Vascular Age : 69 to 71 yrs Insufficient data input for FRAMINGHAM risk analysis	Parameter	Unit	Normal Value	Observed Value	Significance*
CARDIOVASCULAR INTERPRETATION*	Heart Rate	BPM	60 to 100	69.5	HR is low-Normal.
Total CardioVascular risk grade :Moderate with Severe Arterial Stiffness.	Blood Pressure	mmHg	120 / 80	136 / 88	Hi-Normal Blood Pressure
CLINICAL RECOMMENDATIONS:	Pulse Pressure	mmHg	Less than 50	48	Normal Pulse Pressure
Homocysteine test recommended.	Right baPWV	cm/s	Less than 1306.56	1925.7	Severe CA Stiffness
HbA1c test may be advisable.	Left baPWV	cm/s	Less than 1306.56	1941.5	Severe CA Stiffness
THERAPEUTIC SUGGESTIONS**:	C-F PWV	cm/s	Less than 868.48	1377.9	Severe Aortic Stiffness
Systemic vascular therapy required. : Strong Consider Medium dose combo:ACEI/ARB/CCB	R Bra ASI	mmHg	20 to 70	33.8	Normal rbASI
	L Bra ASI	mmHg	20 to 70	38.8	Normal lbASI
	R Ank ASI	mmHg	20 to 70	47.5	Normal raASI
	L Ank ASI	mmHg	20 to 70	37.3	Normal laASI
	R - ABI	--	0.9 to 1.35	1.12	ABI Normal:Peripheral ASO may be absent
	L - ABI	--	0.9 to 1.35	1.11	ABI Normal:Peripheral ASO may be absent
	Ao Sys	mmHg	Less than 117	125	Mild increase in Ao Sys
	Ao PP	mmHg	Less than 36	39	Borderline increase in Ao PP
	Ao Dia	mmHg	Greater than 89	86	Mild decrease in Ao Dia
	Ao AugP	mmHg	Less than 7	13	Moderate increase in Ao Aug P
	Alx (Alx@HR75)	%	Less than 15(17)	34(36)	High increase in Ao Alx

* To be clinically correlated.
** Suggestive therapy only. Actual therapy must be decided by the Physician.
Please ensure compatibility and avoid contraindications.

Abbr.: CA - Central Arterial, PA - Peripheral Arterial, PWV - Pulse wave velocity, baPWV - Brachial Ankle PWV, C-F PWV - Carotid Femoral PWV
ASI - Arterial Stiffness Index, ASO - Atherosclerosis obliterans, Ao - Aortic, Aug - Augmentation, Alx - Augmentation Index
Also refer to Waveforms & Osc. Envelopes to depict CV risk.
Pressure waveforms with sharp peak (Fast Rise and fall) are normal. Blunted peaks and flat waveforms are abnormal.
Oscillometric envelopes with a temple shape are normal. Other shapes depict abnormal conditions of various types.
©2003-20 All rights reserved. PERI2013SW071319. Physician

Fig. 1. Typical PeriScope test report of a Severe Patient in the COVID-19 ICU

Sr. No.	Parameter	Mild(1)	Moderate(2)	Severe(3)	All	P-value		
						Grp1-2	Grp2-3	Grp1-3
1	Sex(M/F)	13/10	18/3	11/9	42/22	-	-	-
2	Age(yrs)	37.87±13.36	45.29±13.07	50.50±12.56	44.25±13.85	0.0701	0.2007	0.0028*
3	Wt(Kg)	61.96±13.32	70.14±12.75	59.05±10.12	63.73±12.89	0.0438*	0.0038*	0.4307
4	Ht(cm)	162.8±8.574	167.9±8.402	161.7±7.680	164.1±8.555	0.0541	0.0174*	0.6403
5	BMI(Kg/m2)	23.18±3.547	24.78±3.492	22.47±2.532	23.48±3.334	0.1405	0.0207*	0.4605

Values are expressed as Mean±SD. *Significant difference in mean values.

Table 1. Demographic characteristics as per COVID-19 severity in the present study

Sr. No.	Parameter	Mild(1)	Moderate(2)	Severe(3)	P-value		
					Grp1-2	Grp2-3	Grp1-3
1	Resp.rate(BrPM)	20.87±1.180	22.33±4.139	29.55±13.19	0.1113	0.0219*	0.0031*
2	FiO2(%)	21.00±0.0	35.48±12.68	57.85±23.13	<0.0001*\$	0.0004*	<0.0001*\$
3	SpO2(%)	97.30±1.428	96.48±2.136	96.50±2.236	0.1350	0.7994	0.0861
4	S/F ratio	463.4±6.801	304.1±101.6	195.9±82.33	<0.0001*	0.0006*	<0.0001*

Values are expressed as Mean±SD. *Significant difference in mean values. \$Mann-Whitney 't' test

Table 2. Categorization criteria as per COVID-19 severity in the present study




Fig.2: Patients Demography a. Age, b. Weight, c. Height, d. BMI

Fig. 2




Fig. 3 Patient Categorization a. Respiration Rate, b. FiO2%, c. SpO2%, d. SpO2%/FiO2% ratio

As the 'normal' value of arterial stiffness is a function of a person's chronological age [31], (i.e. the normal value of Arterial stiffness goes on increasing with age), the real measure of abnormal increase in Arterial stiffness is the difference of the 'predicted' cfPWV value of a 'normal' subject of that age and actually measured cfPWV. Hence, Arterial Stiffness was analyzed using the values of Carotid Femoral Pulse Wave velocity (cfPWV) and increase in cfPWV from the age dependent normal value. Also, in our study, the regression analysis between cfPWV and HR showed very low correlation ($\text{Multiplier} = 0.2180$, $r^2 = 0.04754$, $P = 0.0835$). Hence, the effect of HR on cfPWV values is negligible. It can very safely be stated that the findings about arterial stiffness from the study are independent of effect of HR. No other parameters like Heart rate or Pulse Pressure showed consistent increase in their mean values between Mild, Moderate and Severe groups. Heart Rate (Mild: 76.06 ± 14.47 BPM, 95% CI 69.81 to 82.32; Moderate: 78.20 ± 17.20 BPM, 95% CI 70.36 to 86.03; Severe: 98.07 ± 18.58 BPM, 95% CI 89.37 to 106.8), Brachial Pulse Pressure (Mild: 38.04 ± 7.957 mmHg, 95% CI 34.60 to 41.48; Moderate: 45.95 ± 9.113 mmHg, 95% CI 41.80 to 50.10; Severe: 42.40 ± 12.09 mmHg, 95% CI 36.74 to 48.06) respectively. Refer Fig. 4 for the graphical comparison. On the other hand, the differences in the measurements of Arterial Stiffness parameters were extremely significant in all three groups. All the Arterial stiffness measurements showed uniformity in trends and almost same rise as per the severity of COVID-19 disease. More importantly, since no confounding factor or dependent parameter was found in the statistical analysis of the data, Arterial Stiffness measures stood out as independent and consistent indicators of severity grade. The analysis of Arterial Stiffness parameters is as given in Table 3. These results can be properly visualized in comparison with the earlier graphs. Figure 5 gives a clear idea about the extremely statistically significant elevation of all Arterial Stiffness measurements across patient groups. The Figure 5a shows values of cfPWV in all three patient categories. Figure 5b shows Age Normalized increase in cfPWV.

Discussion

The SARS-CoV-2 virus uses the same system of cell entry, which is triggered by binding of the viral spike (S) protein to angiotensin-converting enzyme 2 (ACE2) on the surface of the host cell. It is clearly evident that the full endothelial layer is affected throughout the body and the disease called Endotheliitis sets in due to COVID-19 infection. The Lancet article [33] shows clear images with endothelial layer involvement. Chen *et al* [34] in their epidemiological studies show that COVID-19 patients admitted to hospital or to an intensive care unit (ICU) present frequently with accompanying conditions such as advanced age, hypertension, diabetes, and cardiovascular diseases implying compromised endothelial integrity may be playing a major part in COVID-19 mortality. Acute bilateral limb ischaemia (ALI)

was observed in young and seemingly healthy patients without any history of atherosclerosis, atrial fibrillation, or pre-existing blood clotting disorders indicating that COVID-19 infection might increase the incidence of ALI and be associated with poorer surgical results owing to the associated acquired hypercoagulability. [35] Explaining the potential role of Endothelial Dysfunction and endothelial layer compromise in COVID-19, the article in Cardiovascular Research [36] shows that Chronic Endothelial Dysfunction may lead to acute vascular inflammation under the attack of SARS-CoV-2 Virus. Prior chronic Endothelial impairment and/or direct viral infection of endothelial cells may work in tandem into a breakdown of endothelial function. Since endothelial layer is present everywhere throughout the vascular system in non-fenestrated form (in the arteries, lungs or the Heart), continuous non-fenestrated form (in the kidneys) and in the discontinuous form (in the liver), the acute endothelial function failure may lead to pathogenesis of sudden severe conditions in various organs. It may manifest as pneumonia and ARDS in the respiratory system, induce microcirculation disorders/myocardial injury in the heart, translate into activation of the coagulation pathway causing thrombosis or develop into tissue damage in the brain and in the kidneys. The overall vasculature is affected very quickly by this disease. The cfPWV which we observed in severe COVID-19 patients was higher than the cfPWV in patients with long term chronic diseases like ESRD, CAD, DM etc. For example, in CAD patients, it was 1204 ± 301.8 cm/s. [24-25] This indicates that COVID-19 damage to the vasculature within less than 15 days is comparable to the damage caused by CAD in number of years. Our COSEVAST study had very strict exclusion criteria. All patients with known Diabetes and Hypertension were excluded. Patients with all other cardiovascular diseases and related surgical intervention/therapy were excluded. Patients with high obesity, history of smoking were also excluded. This was necessary to eliminate basal deviation of arterial stiffness from the normal vasculature. These exclusions reduced the total number of study subjects but removed any selection bias and amplified the validity of our findings. A similar large scale, longitudinal, multi-centric study (COVID-19 ARTERIAL stiffness and vascular Aging CARTESIAN Study) [37] has been proposed and our study will try to follow harmonization with that study. Based on the findings of the present COSEVAST study, another interventional study will be undertaken in the near future to assess various drugs to reduce the abnormal increase of arterial stiffness in COVID-19 patients. The proposed study will be very helpful in establishing the most efficacious therapy in reducing COVID-19 complications. To the best of our knowledge, this is the first study to independently observe significant functional changes in vasculature due to arterial inflammation in COVID-19 patients in terms of non-invasive measures of Arterial stiffness.

Limitations

As for the limitations, any of the patients did not abstain from the standard therapy to alleviate the COVID-19 disease




Fig.4 Related measurements in the study - a. Heart Rate, b. Brachial Pulse Pressure

Sr. No.	Parameter	Mild(1)	Moderate(2)	Severe(3)	P-value		
					Grp1-2	Grp2-3	Grp1-3
1	cfPWV(cm/s)	829.1±139.2	1067±152.5	1416±253.9	<0.0001*	<0.0001*	<0.0001*
2	cfPWV/increase#(cm/s)	101.2±126.1	279±114.4	580.1±216.4	<0.0001*	<0.0001*	<0.0001*

Values are expressed as Mean±SD. *Significant difference in mean values. #Age Normalized.

Table 3. Patient Arterial Stiffness measures as per COVID-19 severity in the present study




Fig. 5 Arterial Stiffness measurements of COVID-19 Patients a. cfPWV, b. Age normalized increase in cfPWV

symptoms since it was only an observational study. The sample size were very small. However, the therapy was uniform intra-group and did not include any drug which could alter the arterial stiffness of the patients. Especially, the therapy of Moderate and Severe groups was identical except the difference in Oxygen supplementation volume. We wanted to conduct multiple follow-up tests to find any trends in Arterial Stiffness, however it proved almost impossible to study patients with COVID-19 disease because of various reasons like changing status of the patient condition, restrictions on research staff movements and sometimes unfortunate death of the patients during the study. We are also in the process of undertaking a medium-term follow-up study of the patients in the present study after their discharge. These subjects will be observed for changes in Arterial Stiffness and occurrence of Cardiovascular disease, if any, over a period of 12 months with the PeriScope device.

Conclusions

The results of this study establish non-invasive measurement of Arterial Stiffness as an independent severity marker in COVID-19 patients. It also strongly indicates that regular assessment and regulation of Arterial Stiffness by titration of therapeutics may reduce acute cardiovascular complications and mortality in COVID-19 patients significantly.

Authors' Contributions

Dr. Sanjeev Kumar: Supervision, Project administration, writing–review editing
Dr. Neeraj Kumar: Conceptualization, data curation, formal analysis, writing–original draft, writing–review editing
Dr. Abhyuday Kumar: Methodology, data curation, writing–review editing
Dr. Divendu Bhushan: Methodology, data curation, writing–review editing
Dr. Amarjeet Kumar: Methodology, data curation, writing–review editing
Dr. Ajeet Kumar: formal analysis, writing–review editing
Dr. Veena Singh: writing–review editing
Dr. Prabhat K Singh: Conceptualization, supervision, visualization.

Conflict of Interest

All the authors declare no conflict of interest.

Funding

No external funding.

References

1. Sarvepalli D. Coronavirus Disease 2019 A Comprehensive Review of Etiology, Pathogenesis, Diagnosis, and Ongoing Clinical Trials. *Cureus*. 2020;12(5):e8076. Published 2020 May 12. doi:10.7759/cureus.8076
2. Shang, J., Ye, G., Shi, K. et al. Structural basis of receptor recognition by SARS-CoV-2. *Nature* 581, 221–224 (2020). <https://doi.org/10.1038/s41586-020-2179-y>
3. Markus Hoffmann, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, *Cell*, Volume 181, Issue 2, 2020, Pages 271-280. e8, ISSN 0092-8674, <https://doi.org/10.1016/j.cell.2020.02.052>.
4. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ Res*. 2020;126(10):1456-1474. doi:10.1161/CIRCRESAHA.120.317015
5. Zemlin AE, Wiese OJ. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). *Ann Clin Biochem*. 2020;57(5):339-350. doi:10.1177/0004563220928361
6. Nicholas S. et al. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. *Circulation*. 2020; 141:1903–1914. DOI: 10.1161/CIRCULATION-AHA.120.047349
7. Guzik et al. COVID-19 and the cardiovascular system implications for risk assessment, diagnosis, and treatment options. *Cardiovasc Res*. doi:10.1093/cvr/cvaa106
8. Daniel A. Duprez Arterial Stiffness and Endothelial Function Key Players in Vascular Health. *Hypertension* Volume 55, Issue 3, 1 March 2010, Pages 612-61 <https://doi.org/10.1161/HYPERTENSIONAHA.109.144725>
9. Stefanadis C, Dernellis J, Tsiamis E, Stratos C, Diamantopoulos L, Michaelides A, Toutouzas P. Aortic stiffness is a risk factor for recurrent acute coronary events in patients with ischaemic heart disease. *Eur Heart J*. 2000;21:390–396.
10. Stefanadis C, Wooley CF, Bush CA, Kolibash AJ, Boudoulas H. Aortic distensibility abnormalities in coronary artery disease. *Am J Cardiol*. 1987;59:1300–1304.
11. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse velocity as a marker of cardiovascular risk in hypertensive patients. *Hypertension*. 1999;33:1111–1117.
12. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension*. 2001;37:1236–1241.
13. Nichols WW, O'Rourke MF, editors. McDonald's Blood Flow in Arteries. 4th ed. London, UK: Edward Arnold; 1998:170–222, 284–315, 347–395, 450–476. 11
14. Jae et al. Acute Systemic Inflammation Increases Central Blood Pressure and Pulse Wave Velocity in Healthy Subjects. *Circulation*. 2009;120:S1006
15. Vlachopoulos et al. Acute Systemic Inflammation Increases Arterial Stiffness and Decreases Wave Reflections in Healthy Individuals. *Circulation*. 2005;112:2193–2200
16. Matthew A et al. Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System. *Hypertension* 2020; 76:1350-1367. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15948>
17. Clinical Presentation of People with SARS-CoV-2 Infection Last Updated: October 9, 2020 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-presentation/>
18. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension: Guidelines Committee. *J Hypertens*. 2003;21:1011–53.
19. 2007 Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) *J Hypertens*. 2007;25:1105–87.
20. Vogel RA, Benitez RM. Noninvasive assessment of cardiovascular risk: From Framingham to the future. *Rev Cardiovasc Med* 2000;1:34-42.
21. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR 3rd. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. *Arterioscler Thromb* 1991;11:1786-94.
22. Khoshdel AR, Carney SL, Nair BR, Gillies A. Better management of cardiovascular diseases by pulse wave velocity: Combining clinical practice with clinical research using evidence-based medicine. *Clin Med Res*. 2007;5:45–52.
23. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html>
24. Naidu MU, Reddy BM, Yashmaina S, Patnaik AN, Rani PU. Validity and reproducibility of arterial pulse wave velocity measurement using new device with oscillometric technique: A pilot study. *Biomed Eng Online*. 2005;4:49.
25. Shridhar Y, Naidu MU, Usharani P, Raju YS. Non-invasive evaluation of arterial stiffness in patients with increased risk of cardiovascular morbidity: A cross sectional study. *Indian J Pharmacol*. 2007;39:294–8.
26. Naidu M.U.R., Reddy C Prabhakar Non-invasive measurement of aortic pressure in patients: Comparing pulse wave analysis and applanation tonometry *Indian J Pharmacol*. 2012;44:2:230-233 12
27. ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH ON HUMAN PARTICIPANTS INDIAN COUNCIL OF MEDICAL RESEARCH NEW DELHI 2006 https://main.icmr.nic.in/sites/default/files/guidelines/ethical_guidelines_0.p
28. Lu, X., Jiang, L., Chen, T. et al. Continuously available ratio of SpO₂/FiO₂ serves as a noninvasive prognostic marker for intensive care patients with COVID-19. *Respir Res* 21, 194 (2020). <https://doi.org/10.1186/s12931-020->

01455-4

29. Bilan N, Dastranji A, Ghalehgalab Behbahani A. Comparison of the spo₂/fio₂ ratio and the pao₂/fio₂ ratio in patients with acute lung injury or acute respiratory distress syndrome. *Journal of Cardiovascular and Thoracic Research*. 2015;7(1):28-31.
30. AmericanHeartAssociation-CPRandFirstAidEmergency Cardiovascular Care. Oxygenation and Ventilation of COVID-19 Patients Module 4: Ventilation Management <https://cpr.heart.org/en/resources/coronaviruscovid19-resources-for-cpr-training/oxygenation-and-ventilation-of-covid-19-patients>
31. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values' The Reference Values for Arterial Stiffness' Collaboration *European Heart Journal* doi:10.1093/eurheartj/ehq165
32. Ian B. Wilkinson, Helen MacCallum, Laura Flint, John R. Cockcroft, David E. Newby and David J. Webb the influence of heart rate on augmentation index and central arterial pressure in humans *Journal of Physiology* (2000), 525.1, pp.263–270
33. Varga et al. Endothelial cell infection and Endotheliitis in COVID-19 *The Lancet* VOLUME 395, ISSUE 10234, P1417-1418, MAY02, 2020
34. Chen T et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020;368:m1091.
35. Bellosta R, Luzzani L, Natalini G, et al. Acute limb ischemia in patients with COVID-19 pneumonia published online ahead of print, 2020 Apr 29. *J Vasc Surg*. 2020; S0741-5214(20)31080-6.
36. Bermejo-Martin JF, Almansa R, et al. COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction, *Cardiovascular Research*, Volume 116, Issue 10, 1 August 2020, Pages e132–e133, <https://doi.org/10.1093/cvr/cvaa1401>.
37. <http://www.arterysociety.org/our-activities-2/cartesian-2/>

Research in context

A. Evidence before this study. The exact nature of the SARS-CoV-2 viral infection and its manifestation as COVID-19 disease is a matter of an ongoing discussion. Based on prior knowledge, it can be safely stated that COVID-19 is not solely a Respiratory system disease involving lungs. It also affects other bodily systems with target organ damage like Cardiovascular (Heart), Nervous system (Brain), Digestive (Bowels) as well as Renal (Kidneys). The common factor in all these systems is the vascular Endothelial layer in various forms. Pathological and clinical case study findings have shown Endotheliitis pervasive in COVID-19 cases. This leads to the hypothesis that acute functional compromise of vasculature leads to failure of various systems and organs in severe COVID-19 patients. Control and reversal of this damage may reduce the morbidity and mortality risk.

B. Added value of this study. Although there is some pathological evidence of structural damage to the endothelial layer in COVID-19 patients, the systemic functional deterioration in the vasculature has not been studied. Our study is first of its kind to prove the functional deterioration of Arterial system in terms of abnormal increase in arterial stiffness as the probable cause of severity in COVID-19. Our findings strongly suggest that arterial stiffness can be an independent and accurate marker for objective risk stratification and therapeutic alleviation of acute cardiovascular complications like MODS (multiple organ distress syndrome) in COVID-19.

C. Implications of all the available evidence. The basis of our study and its findings suggest that arterial stiffness measurement can be added as a simple and accurate measurement for objective risk stratification in COVID-19 patients. Early detection, monitoring and therapeutic control of Arterial Stiffness in COVID-19 patients may reduce acute cardiovascular complications. Arterial stiffness may be used as an independent marker for treatment and prognosis in COVID-19 patients.